Jodi Rintelman writes her debut elf blog on the first randomised controlled trial on the efficacy and safety of intranasal esketamine as an adjunctive treatment to antidepressants for treatment-resistant depression.
[read the full story...]
Kathryn Walsh reports on a recent Cochrane systematic review of pharmacotherapies for cannabis dependence, which concludes that there is a lack of evidence for all medications reviewed.
[read the full story...]
Two of the most widely available medicines for dementia in the UK are cholinesterase inhibitors and a N-methyl-D-aspartate (NMDA) receptor antagonists (NHS, 2013). Both drugs are popular because they have been found to lead to improvements in dementia symptoms (Raina 2008). However, some have raised concerns about the safety for patients. These concerns are partly [read the full story…]
The review and re-appraisal of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease has resulted in a change in the guidance. Specifically: donepezil, galantamine and rivastigmine are now recommended as options for managing mild as well as moderate Alzheimer’s disease, and memantine is now recommended as an option for managing moderate Alzheimer’s [read the full story…]
